Mometason Cipla (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. The drug‑receptor complex then moves to the cell nucleus and alters gene expression, decreasing the production of inflammatory cytokines and chemokines. This reduces swelling, mucus production, and immune‑cell infiltration, providing anti‑inflammatory relief.

The appropriate dose of Mometason Cipla is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product’s labeling; no standard dose is provided here.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mometason Cipla.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Mometason Cipla (mometasone furoate) is a high‑potency intranasal corticosteroid with minimal systemic absorption, similar to fluticasone propionate. Compared with some older steroids, it often provides effective symptom control at lower daily doses, but choice of agent depends on individual response, tolerability, and prescriber preference.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Protect it from moisture and direct sunlight. Do not freeze the product. Keep the device upright and avoid exposing the nozzle to contaminants.

Mometason Cipla is delivered as a nasal spray. The patient should gently blow the nose, insert the tip into one nostril, close the opposite nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes or cataract formation, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal passages. Patients should seek immediate medical attention if they experience any of these events.

Mometason Cipla should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or in children for whom safety has not been established, unless specifically directed by a physician.